1. What is your company’s lead product or technology?
Omnitram (O-desmethyltramadol) is a novel oral analgesic developed by Syntrix that alleviates pain via a dual mechanism involving mu-opioid receptor activation and inhibition of the reuptake of norepinephrine. Omnitram is in clinical development and has just completed a Phase 1b double-blind, placebo-controlled clinical trial (N=40) in experimental pain.
2. What sets your company apart from competitors?
Omnitram is a proprietary solution for pain relief that is thought to be less addictive than traditional opioids and capable of treating a wider spectrum of pain types than traditional opioids. Omnitram is active without requiring metabolic activation. Other available analgesics require metabolic activation and are ineffective in many patients due to genetics or drug-drug interactions. Omnitram exploits the active metabolite of an FDA approved analgesic and may offer a shortened and less costly regulatory path to approval.
3. What has been your company’s most exciting recent accomplishment or milestone?
The Omnitram IND opened in March 2014. Syntrix was able to start and complete enrollment of the Phase 1b trial within only seven months of opening the IND, hitting this milestone well ahead of schedule.
4. How has the NIH SBIR program helped you in working to achieve your long-term goals? (50-75 words)
Drug development is a long and difficult path that requires patience and a reliable capital source. For Syntrix, the NIH SBIR program has been that patient and consistent source of capital. With over $25 million in NIH SBIR capital raised to date, the NIH SBIR program has allowed us to successfully mature our drug pipeline from early discovery stage on through phase 2 clinical testing.
5. What do you hope to accomplish through your company presentation and participation at the BIO Investor Forum?
Connect with potential strategic pharmaceutical partners and equity investors.
6. Tell us something about your company that investors might not know.
Syntrix has two other drug candidates in its clinical pipeline. SX-682 is a novel oral CXCR1/2 inhibitor being developed for cancer and inflammatory diseases such as COPD. The IND for SX-682 is scheduled to open in the next year. LD-aminopterin is a once-a-week oral therapy in phase 2 clinical testing for inflammatory diseases that include psoriasis and rheumatoid arthritis. Each of the three drug candidates in the Syntrix pipeline are directed to multi-billion dollar therapeutic markets.
Click here to learn more about BIO Investor Forum.